Cargando…
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
BACKGROUND: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR). We assessed multiple ascending doses of berzosertib + gemcitabine ± cisplatin in patients with resistant/refractory advanced sol...
Autores principales: | Middleton, Mark R., Dean, Emma, Evans, Thomas R. J., Shapiro, Geoffrey I., Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368196/ https://www.ncbi.nlm.nih.gov/pubmed/34040175 http://dx.doi.org/10.1038/s41416-021-01405-x |
Ejemplares similares
-
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
por: Shapiro, Geoffrey I., et al.
Publicado: (2021) -
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020) -
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
por: Terranova, Nadia, et al.
Publicado: (2020) -
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
por: Hall, Amy B., et al.
Publicado: (2014) -
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
por: Telli, Melinda L., et al.
Publicado: (2022)